SJ-01 is under clinical development by Shanghai Bao Pharmaceuticals and currently in Phase I for Anemia. According to GlobalData, Phase I drugs for Anemia have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SJ-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SJ-01 is under development for the treatment of anemia.
Shanghai Bao Pharmaceuticals overview
Shanghai Bao Pharmaceuticals (Bao Pharma) operates in the healthcare sector. Bao Pharma is headquartered in Shanghai, China.
For a complete picture of SJ-01’s drug-specific PTSR and LoA scores, buy the report here.